Related Experiment Video
Updated: May 2, 2026

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Double-positive CD4(+)CD8(+) Sézary syndrome: an unusual phenotype with an aggressive clinical course
Raymond Wu, Jonathan H Zippin, Cynthia Magro1
1Box 58, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Room F-309, 1300 York Ave, New York, NY 10065, USA. cym2003@med.cornell.edu.
Abstract:
Sézary syndrome (SS) is a rare, aggressive form of cutaneous T-cell lymphoma. When patients die from SS, it frequently is due to the sequela of the profound endogenous immunosuppression that is typical of this condition. Most cases of SS represent neoplasms of mature postthymic CD4(+) T cells. We present a case of SS that exhibited an unusual double-positive phenotype in which the neoplastic T cells demonstrated CD4 and CD8 expression. The patient's clinical course was unusually aggressive with rapid clinical demise occurring less than 1 year from the initial cutaneous eruption. Our patient had documented involvement of the skin, peripheral blood, and lymph nodes. We also review other anecdotal reports of postthymic T-cell lymphomas manifesting as a double-positive phenotype primarily in the context of adult T-cell leukemia and T-cell lymphoma. The evolution of the postthymic double-positive T-cell phenotype, especially with regard to SS, and the benign lymphocyte counterpart also is discussed.
Related Concept Videos
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Cytomegalovirus Disease
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

